Actively Recruiting
Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation
Led by West China Hospital · Updated on 2024-08-07
12
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
Sponsors
W
West China Hospital
Lead Sponsor
B
Beijing Pins Medical Co., Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
Major depressive disorder (MDD) is a complex and severe mental illness, characterized by multiple symptoms, and is a leading cause of non-fatal health loss. Despite this, approximately 30% of patients do not respond to standard pharmacological or psychological treatments. Currently, we lack objective brain-based biomarkers to differentiate between natural mood fluctuations and situations requiring intervention. To address this issue, we employed a novel electrophysiology recording device and applied deep brain stimulation (DBS) to 12 MDD patients. Our study aims to use long-term invasive neural signal collection and machine learning techniques to reveal the complex relationship between these signals and depressive symptoms. By applying advanced machine learning algorithms, our goal is to establish highly accurate prediction models to identify biomarkers associated with the occurrence and progression of depression. The research will focus on the spatiotemporal features of neural signals and build personalized depression decoding models based on individual differences through the integration and analysis of large-scale data. By delving into the information contained in neural signals, we hope to contribute to the development of personalized treatment approaches for depression.
CONDITIONS
Official Title
Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must sign a research informed consent form before starting any study procedures
- Age between 16 and 30 years, any gender
- Diagnosed with Major Depressive Disorder (MDD) based on DSM-V criteria
- Current depressive episode lasting 2 or more years, or recurrent episodes with at least 4 episodes and current episode at least 1 year
- Failed at least 3 courses of adequate antidepressant therapy using 2 or more classes of antidepressants and refused, could not tolerate, or found electroconvulsive therapy ineffective
- Have a HAMD-17 score of 20 or higher or a MADRS score of 25 or higher
- Able to communicate effectively and provide written informed consent along with legal guardian
You will not qualify if you...
- Diagnosis of bipolar disorder, schizoaffective disorder, schizophrenia, or other psychotic disorders
- Severe personality disorders
- Severe physical diseases or organic brain diseases
- Alcohol or substance abuse or dependence diagnosed within 1 year prior to screening
- Surgical contraindications such as significant medical conditions or inability to stop anticoagulation medications
- Structural brain abnormalities seen on MRI within 1 year prior to screening
- MRI contraindications excluding DBS implantation or device
- Pregnant or breastfeeding
- Enrolled in another unrelated study
- Any condition that may endanger safety or prevent successful participation, including family, medical, psychological, social, or geographic factors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West CHina Hospital,Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
W
wei wang, M.D.
CONTACT
B
Botao Xiong, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here